Sort
10,766 grants matching “checkpoint inhibitor”
Antifungal Immunity and the Mechanism of Fungal Programmed Cell Death
$653,049Tobias M Hohl · Sloan-Kettering Inst Can Research · R01 · FY2020 · AI
Antifungal Immunity and the Mechanism of Fungal Programmed Cell Death
$653,049Tobias M Hohl · Sloan-Kettering Inst Can Research · R01 · FY2023 · AI
Precision targeting of T cell cytotoxicity with PET
$652,933Michael John Evans · University Of California, San Francisco · R01 · FY2022 · CA
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
$652,762Jin Wang · Baylor College Of Medicine · R01 · FY2022 · CA
Antibody Drug Conjugate Designs to Enhance the Therapeutic Window for Brain Tumors
$652,751Jann N Sarkaria · Mayo Clinic Rochester · R01 · FY2025 · NS
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
$652,695Pawel K. Mazur · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Tunneling Nanotube Inhibitors for Cancer Immunotherapy
$652,634Shiladitya Sengupta · Brigham And Women'S Hospital · R01 · FY2023 · CA
Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer
$652,414Nupam P Mahajan · Washington University · R01 · FY2024 · CA
Microtubule Regulation
$652,315Don W. Cleveland · Ludwig Institute For Cancer Res Ltd · R01 · FY2010 · GM
Antigen-specific âkick and killâ of the latent HIV reservoir using dendritic cells
$652,156Robbie B Mailliard · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · AI
Image-guided ultrasound therapy and drug delivery in pancreatic cancer
$652,017Katherine W Ferrara · Stanford University · R01 · FY2018 · CA
Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma
$651,814Veronika Fedirko · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
$651,354Stuart J Kahn · Syntrix Biosystems, Inc. · R44 · FY2021 · CA
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer
$651,173Nirav Thosani · University Of Texas Hlth Sci Ctr Houston · R01 · FY2025 · CA
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
$650,786Alexander Robertson Allan Anderson · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2019 · CA
Developing a novel combination immunotherapy for triple-negative breast cancer
$650,749Naoto T Ueno · University Of Hawaii At Manoa · R01 · FY2025 · CA
Microtubule Regulation
$650,614Don W. Cleveland · Ludwig Institute For Cancer Res Ltd · R01 · FY2015 · GM
Microtubule Regulation
$650,614Don W. Cleveland · Ludwig Institute For Cancer Res Ltd · R01 · FY2012 · GM
Microtubule Regulation
$650,614Don W. Cleveland · Ludwig Institute For Cancer Res Ltd · R01 · FY2014 · GM
Drug eluting injectable biomaterials for next generation chemoembolization
$650,424Rahmi Oklu · Mayo Clinic Arizona · R01 · FY2022 · CA
Immune correlates of LTBI in HIV-exposed infants
$650,269Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2019 · AI
Image-guided ultrasound therapy and drug delivery in pancreatic cancer
$650,148Katherine W Ferrara · Stanford University · R01 · FY2020 · CA
Adaptive Symptom Self-Management to Reduce Psychological Distress and Improve Symptom Management for Survivors on Immune Checkpoint Inhibitors
$650,104Terry A Badger · University Of Arizona · R01 · FY2022 · CA
Exploiting A Critical Vulnerability To Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC)
$650,089Mark Yarchoan · Johns Hopkins University · R01 · FY2024 · CA
Imaging tumor and T cell responses to metabolic and immune modulation therapy
$650,075Taha Merghoub · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA